GenoMed Agrees to Distribute Healthcare to India for Under $150 Per Patient Per Year
FOR IMMEDIATE RELEASE
Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
St. Louis, Missouri
www.genomed.com
Tel. 314-983-9933
Email: dwmoskowitz@genomed.com
Ms. Sujata Mital
Director, SUMIT Exports & Trades pvt. Ltd.
Mumbai, India
www.sumitbiomedical.com
Email: sumit_exports@yahoo.com
ST. LOUIS, April 12, 2006 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company whose business is public health™, announced today that it has entered into an exclusive agreement with SUMIT Exports & Trades to market its services to India for under US $150 per patient per year. Since the per capita income in India is around $600 a year, GenoMed has priced its Next Generation DM™ service within reach of the average Indian citizen.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "In 2002, we published that we can reverse chronic kidney failure from diabetes and high blood pressure, as well as significantly delay the progression of emphysema. Third World countries like India want to enjoy better health, but can't afford to spend $2 trillion a year on healthcare as the U.S. currently does. Thanks to medical genomics, GenoMed can already deliver better outcomes for cardiovascular disease, which two-thirds of people in First World countries like the U.S. die of. And we have a good jump on cancer, which a third of Americans die of."
Continued Dr. Moskowitz, "Yesterday, at the BIO 2006 convention in Chicago, former President Clinton called biotechnology the answer to international healthcare. Today, we're delighted to prove him right. We look forward to the expansion of President Bush's Health Savings Accounts (HSA's) to make preventive molecular medicine and lower health care costs a reality in the United States one day, too."
About GenoMed™
GenoMed is the only biotechnology company serious about both lowering healthcare costs and improving patient outcomes. It is leading the clinical revolution made possible by knowing which genes cause which diseases. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip®, on a research basis only, to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in Caucasians. And GenoMed is in the process of creating a virtual pharmaceutical company to develop new drugs for the hundreds of cancer chemotherapy targets it has discovered, in situations where no drug yet exists.
|
